A 28-year-old male from Delhi with a family history of hereditary persistence of fetal hemoglobin (HPFH) is found to have elevated HbF (18%) on hemoglobin electrophoresis during a routine health screening. Genetic analysis reveals a point mutation in the γ-globin gene promoter (−175 T→C) that disrupts a transcriptional silencer element. RNA-seq of reticulocytes shows increased γ-globin mRNA abundance relative to β-globin mRNA. The patient is asymptomatic with normal hemoglobin and hematocrit. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This patient has hereditary persistence of fetal hemoglobin (HPFH), a benign genetic condition in which γ-globin gene expression persists into adulthood due to mutations in transcriptional regulatory elements (silencers or enhancers). The patient is asymptomatic and hematologically normal. ## Why Genetic Counseling & Cascade Screening is the Next Step **Key Point:** HPFH is a benign, autosomal dominant condition that requires NO treatment in asymptomatic individuals. The appropriate next step is genetic counseling to: 1. Reassure the patient about the benign prognosis 2. Identify at-risk family members who may carry the same mutation 3. Clarify inheritance pattern and recurrence risk in offspring **High-Yield:** HPFH is clinically benign because: - HbF (γ~2~δ~2~) has higher oxygen affinity than HbA (α~2~β~2~), providing a *protective* effect - Patients remain asymptomatic throughout life - No hemolysis, anemia, or vaso-occlusive complications occur - Life expectancy is normal ## Distinction: HPFH vs. β-Thalassemia | Feature | HPFH | β-Thalassemia Major | |---------|------|---------------------| | **Cause** | Silencer mutations → persistent γ-globin expression | β-globin gene mutations → absent/reduced β-globin | | **HbF level** | 15–30% | 50–90% | | **Clinical phenotype** | Asymptomatic, normal Hb | Severe anemia, hemolysis, organ damage | | **Management** | Genetic counseling only | Transfusion, chelation, transplant | | **Prognosis** | Normal lifespan | Shortened lifespan without treatment | **Clinical Pearl:** The key distinguishing feature is that HPFH patients have *normal* hemoglobin levels and *no* hemolysis. The elevated HbF is a compensatory mechanism that does not cause disease. ## Why Other Options Are Inappropriate **Splicing analysis of γ-globin** — The mutation is in the *promoter* (transcriptional silencer), not in splice sites. The γ-globin transcripts are correctly spliced; the problem is *increased transcription* due to loss of the silencer element. Splicing analysis is unnecessary and will not change management. **Folic acid and B12 supplementation** — While these support erythropoiesis, they are indicated only in patients with evidence of nutritional deficiency or hemolytic anemia. This patient has normal hemoglobin and no clinical evidence of hemolysis. Supplementation is not indicated and adds unnecessary treatment burden. **Hydroxyurea therapy** — Hydroxyurea increases HbF production and is indicated in symptomatic sickle cell disease or β-thalassemia major to reduce vaso-occlusive crises and hemolysis. This patient has HPFH (a benign condition), is asymptomatic, and has normal hemoglobin. Administering hydroxyurea would expose him to unnecessary toxicity (myelosuppression, teratogenicity) without clinical benefit. ## Management Algorithm for Elevated HbF ```mermaid flowchart TD A[Elevated HbF on screening]:::outcome --> B{Clinical symptoms or anemia?}:::decision B -->|Yes| C{Hemolysis present?}:::decision B -->|No| D[Likely HPFH or other benign variant]:::outcome C -->|Yes| E[β-Thalassemia major or sickle cell]:::outcome C -->|No| D D --> F[Genetic testing for silencer mutations]:::action F --> G[Genetic counseling + cascade screening]:::action E --> H[Treat underlying hemoglobinopathy]:::action ``` **Mnemonic:** **HPFH-COUNSEL-ONLY** — Hereditary Persistence of Fetal Hemoglobin requires genetic COUNSELING and family screening ONLY; no disease-modifying therapy is needed in asymptomatic patients.